[go: up one dir, main page]

WO2005041879A3 - Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie - Google Patents

Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie Download PDF

Info

Publication number
WO2005041879A3
WO2005041879A3 PCT/US2004/035949 US2004035949W WO2005041879A3 WO 2005041879 A3 WO2005041879 A3 WO 2005041879A3 US 2004035949 W US2004035949 W US 2004035949W WO 2005041879 A3 WO2005041879 A3 WO 2005041879A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
treating
combinations
phophodiesterase
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/035949
Other languages
English (en)
Other versions
WO2005041879A2 (fr
Inventor
Jaime L Masferrer
Thomas D Penning
Xing Wang
Deborah M Heuvelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to MXPA06004657A priority Critical patent/MXPA06004657A/es
Priority to EP04817484A priority patent/EP1682143A2/fr
Priority to CA002543503A priority patent/CA2543503A1/fr
Priority to BRPI0415896-2A priority patent/BRPI0415896A/pt
Priority to JP2006538292A priority patent/JP2007509968A/ja
Publication of WO2005041879A2 publication Critical patent/WO2005041879A2/fr
Publication of WO2005041879A3 publication Critical patent/WO2005041879A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement ou de prévention de la néoplasie ou d'un trouble associé à la néoplasie chez un sujet. La méthode consiste à administrer au sujet une quantité efficace d'une combinaison associant un inhibiteur de Hsp90 et un inhibiteur de la phophodiestérase, et éventuellement un inhibiteur de Cox-2.
PCT/US2004/035949 2003-10-28 2004-10-28 Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie Ceased WO2005041879A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA06004657A MXPA06004657A (es) 2003-10-28 2004-10-28 Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
EP04817484A EP1682143A2 (fr) 2003-10-28 2004-10-28 Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie
CA002543503A CA2543503A1 (fr) 2003-10-28 2004-10-28 Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie
BRPI0415896-2A BRPI0415896A (pt) 2003-10-28 2004-10-28 combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
JP2006538292A JP2007509968A (ja) 2003-10-28 2004-10-28 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51502103P 2003-10-28 2003-10-28
US60/515,021 2003-10-28

Publications (2)

Publication Number Publication Date
WO2005041879A2 WO2005041879A2 (fr) 2005-05-12
WO2005041879A3 true WO2005041879A3 (fr) 2005-10-06

Family

ID=34549367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035949 Ceased WO2005041879A2 (fr) 2003-10-28 2004-10-28 Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie

Country Status (6)

Country Link
EP (1) EP1682143A2 (fr)
JP (1) JP2007509968A (fr)
BR (1) BRPI0415896A (fr)
CA (1) CA2543503A1 (fr)
MX (1) MXPA06004657A (fr)
WO (1) WO2005041879A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090569B2 (en) 2004-11-18 2015-07-28 Synta Pharmaceuticals Corp. Triazone compounds that modulate HSP90 activity
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
JP2008533090A (ja) * 2005-03-14 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 心血管疾患の防止方法
WO2009049305A2 (fr) * 2007-10-12 2009-04-16 Arqule, Inc. Composés de tétrazole substitués et leurs utilisations
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CA2724413C (fr) * 2008-05-15 2016-10-18 Duke University Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2384752A1 (fr) * 2010-04-14 2011-11-09 Universitätsklinikum Hamburg-Eppendorf Préparation de combinaison contenant un inhibiteur de phosphodiestérase et un inhibiteur de COX destinée au traitement du cancer
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
EP2776025A1 (fr) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Polythérapie d'inhibiteurs de hsp 90 avec des agents contenant du platine
CN103102306A (zh) * 2013-02-06 2013-05-15 河南东泰制药有限公司 一种塞来昔布的制备方法
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN104069113B (zh) * 2014-07-08 2016-08-31 山东大学齐鲁医院 西地那非在制备治疗抗血管瘤的药物中的应用
EP3906029A4 (fr) 2018-12-31 2022-09-21 Biomea Fusion, LLC Inhibiteurs de l'interaction ménine-mll
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
CN112679470B (zh) * 2021-01-06 2023-01-13 中国药科大学 (e)-1-苯基4-烯基-1h-吡唑类化合物及其医药用途
US12251385B2 (en) 2021-08-11 2025-03-18 Biomea Fusion, Inc. Covalent inhibitors of menin-MLL interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO2002094196A2 (fr) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Methode de traitement de cancers associes a des niveaux de her-2 eleves
US6586603B1 (en) * 1993-11-30 2003-07-01 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6586603B1 (en) * 1993-11-30 2003-07-01 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
WO2002094196A2 (fr) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Methode de traitement de cancers associes a des niveaux de her-2 eleves
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090569B2 (en) 2004-11-18 2015-07-28 Synta Pharmaceuticals Corp. Triazone compounds that modulate HSP90 activity
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Also Published As

Publication number Publication date
BRPI0415896A (pt) 2007-01-09
WO2005041879A2 (fr) 2005-05-12
CA2543503A1 (fr) 2005-05-12
EP1682143A2 (fr) 2006-07-26
JP2007509968A (ja) 2007-04-19
MXPA06004657A (es) 2006-06-27

Similar Documents

Publication Publication Date Title
WO2005041879A3 (fr) Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie
WO2005048942A3 (fr) Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
WO2005044194A3 (fr) Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
WO2000038786A3 (fr) Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un antagoniste de l'integrine comme therapie combinee pour traiter les maladies neoplasiques
WO2004080430A3 (fr) Procedes pour ameliorer la qualite de la peau
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2002024613A3 (fr) Derives de resorcine
WO2003015608A3 (fr) Multitherapie pour le traitement du cancer
WO2005000212A3 (fr) Procede de traitement de maladies par des agents inhibiteurs de hsp90 en combinaison avec des inhibiteurs d'exportation nucleaire
WO2008067158A3 (fr) MÉTHODE DESTINÉE À FAVORISER LA POUSSE DES CHEVEUX ET/OU À RETARDER OU TRAITER LA CHUTE DES CHEVEUX PAR ADMINISTRATION D'UN ANTAGONISTE OU D'UN INHIBITEUR DU TGF-β
WO2006023603A3 (fr) Compositions d'inhibiteur pde5 et méthodes de traitement des troubles cardiaques
WO2004096206A3 (fr) Combinaison therapeutique d'un inhibiteur de cox-2 et d'un inhibiteur de tace
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2007109093A3 (fr) Derives de pyrazolo[1,5-a]pyrimidine et procedes d'utilisation de ceux-ci
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2004093856A3 (fr) Combinaison d'un inhibiteur de cox-2 et d'un agent antineoplastique de type d'alkylation destinee au traitement de la neoplasie
EP1332823A4 (fr) Roue d'engrenage, procede et dispositif pour realiser la finition de la face dentee de cette roue d'engrenage
WO2005082375A3 (fr) Methodes permettant de traiter la cystite interstitielle et composes et compositions connexes
WO2004060369A8 (fr) Inhibiteurs de la kynurenine 3-hydroxylase pour le traitement du diabete
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2006009718A3 (fr) Methodes de traitement ou de prevention de la dysfonction erectile ou de l'incontinence urinaire
WO2003018014A3 (fr) Procedes d'inhibition de la formation de canaux vasculaires et procedes d'inhibition de la proliferation
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004817484

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2543503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004657

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006538292

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004817484

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415896

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004817484

Country of ref document: EP